I would say the access framing — let me say it differently — from the component layer our ruggedized miniature DTS modules reached record Q1 sales driven by defense missile-test projects, orders growing for military jet engine and hypersonic missile testing. At this point in time DTS flew on Artemis II, SpaceX Dragon, Blue Origin. I would keep this honest — genuine recurring A&D instrumentation exposure, but broad A&D not drone-specific, assessed outside a drones-first frame until drone-specific disclosure emerges. Anything can happen.

Our HK listing changes access, but the durable fact is our core: HVAC&R and refrigeration components — valves, microchannel heat exchangers, pumps, controllers, sensors — are about 60% of revenue, with a near-exclusive global position in electronic-expansion and solenoid valves built over 30 years. Auto and EV thermal is the other ~40%, a top-tier NEV supply-chain position. Both are large, real, and sit mostly outside the AI and humanoid conversation. The actuator and data-center legs are real but early — trial-production, sample-delivery, not sized, not yet segments.

I would say the access question — let me say it differently — our three segments booked $102.1 million, first above $100 million since 2022, book-to-bill 1.21. At this point in time the profile is AI infrastructure and defense. The honest frame: this sits off three years averaging book-to-bill below 1.0. Adjusted free cash flow negative $3.7 million on working-capital build. Whether orders convert to sustained revenue is the question we are watching, not answering.

Operating cash flow collapsed 85.3% to about 30.7 million yuan, from about 209.0 million a year earlier – and it ran the full year, not just the weak back half: first‑half cash flow was only about 9.0 million versus 108.7 million a year earlier, a 91.8% fall while profit still grew. The cause is a receivables blowout – trade receivables jumped to about 365.3 million yuan, roughly 45% higher, against revenue up only 6.6% – and short‑term borrowings roughly doubled to about 209.5 million yuan, swinging us into net debt.

After a strong FY2025, our first quarter of 2026 decelerated. Headline net profit rose 2.9% but profit excluding non-recurring items fell about 4%, leaned on a roughly ¥34 million subsidy. Revenue was ¥2.10 billion, up 1.5%. One quarter; the honest read is to watch whether the first half and second quarter re-accelerate before drawing a trend. Domestic gear revenue fell 5.9% in FY2025, offset by overseas surge. Whether the Q1 dip is a blip is genuinely open.

I would say the access framing — let me say it differently — unlike peers we disclose and quantify our humanoid line: about $600,000 shipped in Q1 2026, pre-production, expect to more than double in Q2. At this point in time no visibility — two pre-production customers, early talks with two more — so 2025 baseline, ~50% annual growth modeled. Analyst math ~$5M in 2026 vs ~$340M revenue ~1.5%, optionality not base case. Adoption still fairly low, pre-production, anything can happen.

Beyond our humanoid work, we supply specialty precision components for semiconductor manufacturing equipment, and sales there have risen as data‑center and generative‑AI demand expanded, with a rapid order turnaround since early 2026. We note that this semiconductor leg is cyclical, having troughed last year, and we also see aerospace, space and defense as a growth pillar—having met a ¥3 billion space‑revenue target and observing rising defense budgets and easing export rules, especially in Germany.

We trade as a Shanghai A-share (601689) and are A-share-only today. On December 1, 2025 we announced plans to issue H-shares and list in Hong Kong, though the listing is planned but not yet completed and carries some uncertainty. For investors who can access China A-shares directly, our Shanghai listing is already reachable — the Hong Kong listing would open a cleaner route for an international book, not a precondition for ownership. A peer completed a similar A-to-A-plus-H path roughly a year ahead.

I would say the access framing — let me say it differently — for a US-listed component layer, Q1 2026 revenue was $84.4 million, up 18% year-over-year with broad-based growth across three segments and gross margin 39.0% from 37.7%. At this point in time, a small GAAP net loss of $(0.3) million: Q1 seasonally weakest, ~$5 million new organizational cost, unfavorable FX. Adjusted EBITDA $5.9 million, ~7% of revenue. Q2 guided $85-90 million.

In Measurement Systems, ruggedized miniature DTS data-acquisition modules reached record Q1 sales driven by defense missile-test projects, with orders growing for military jet engine and hypersonic missile testing. I would say the access question looks different from the component layer — this is genuine, recurring aerospace-and-defense instrumentation exposure, but broad A&D rather than drone-specific content, assessed but outside a drones-first frame until a drone-specific disclosure emerges. At this point in time, anything can happen.

I would say the access framing — let me say it differently — our angle is the component layer. Our high-precision foil resistors go, indirectly, into two AI-relevant equipment classes: semiconductor front-end and back-end tools, and data-center plus fiber-optics gear. That is the Sensors growth engine, at this point in time. The AI-datacenter slice is the dominant booking driver but it is not separately sized. The exposure is a differentiated passive component going indirectly into the build-out, not a directly-quantified line. Anything can happen.

I would say our new three-year model targets 8-10% compounded annual organic growth, with Sensors and Measurement Systems above that rate and Weighing Solutions below — a favorable mix shift, at this point in time. The step-up is large: FY2025 gross margin 38.9% toward a 46.5% target, Q1 GAAP operating margin 0.4% toward 14.5-15.5%. The model rests on a conservative 2025 baseline given limited visibility and assumes a linear path. We still have to earn it.

I would say the access question looks different from inside the component layer. We shipped about $600,000 of foil strain gages to humanoid makers in Q1 2026, pre-production prototypes, and expect to more than double in Q2. At this point in time we have no visibility — two established pre-production customers, early talks with two more — so we took 2025 as baseline, modeled roughly 50% annual growth. Analyst math of ~$5 million in 2026 against ~$340 million revenue is ~1.5%, optionality not base case. Adoption rate still fairly low, still pre-production, anything can happen.

On data centers, keep the claim exactly as small as the disclosure. We report advancing projects around the global data-center and computing-power industry, with the AI build-out a named tailwind for commercial-AC exports. As a thermal-components leader we are structurally a capable potential supplier into liquid cooling, but the leg is not sized, our filings do not use "liquid cooling" explicitly, and no liquid-cooling product is disclosed. This remains an emerging direction, not a substantiated revenue line.

Our top five customers represent ~65.8% of sales — no single customer above 50%, no related-party sales — concentration well above a typical diversified supplier and tied to a few large EV names. A Tesla link to our actuator leg is widely reported in trade press but not company-confirmed; we name only "leading domestic and international NEV automakers." Overseas revenue was roughly flat in FY2025, with Malaysia and other plants doubling as tariff mitigation. Access routes differ, but concentration is the disclosed fact.

At our core we're a founder-controlled Tier-1 across eight product lines — NVH, interiors, chassis, auto-electronics, thermal, line-controlled brake, air suspension, steer-by-wire — delivering roughly ¥30,000 per vehicle as modular, system-level supply. That auto-parts base is 93% of revenue, with auto-electronics up ~52% in FY2025. Our brake and chassis R&D depth feeds the actuator leg, but the core itself is where margin pressure shows up. Position quality starts with the breadth and depth of the main business.

Tuopu trades as a Shanghai A-share (601689) and is A-share-only today. We announced plans on December 1, 2025 to issue H-shares and list in Hong Kong, though the listing is planned but not yet completed and carries some uncertainty. For investors able to access China A-shares directly, the Shanghai listing is already reachable — the Hong Kong listing would open a cleaner route for an international book, not a precondition for ownership.

Our FY2025 revenue reached ¥29.58B, up 11.2%, but net profit fell 7.4% to ¥2.78B as weighted ROE dropped from 16.6% to 12.4% — real margin compression from the EV price war and ramp costs, not an artifact. Operating cash flow rose 38.5% to ¥4.48B and R&D ran at ¥1.5B (~5% of sales). The profit decline has narrowed from -12% at nine months to -7.4% full year to -2.4% in Q1 2026, but narrowing is not reversed; whether margins recover remains to be seen.

We've stood up a dedicated robotics-actuator division with independent management, in-house permanent-magnet servo and frameless motors, and motor-reducer-controller integration, backed by a ¥5.0B commitment to a 300-mu core-components base. But the leg is still pre-revenue: FY2025 actuator revenue was ~¥13.6M, 0.05% of sales, with no named robot customers in primary filings. The capability is concrete; the revenue isn't there yet, and the humanoid end-market itself is pre-volume — so calling this dominant would be a forward bet, not a current fact.

Bookings were $102.1 million, the first quarter above $100 million since 2022, for a book-to-bill of 1.21. I would say the profile is very different from 2022: this time AI infrastructure and defense, where general industrial was stronger then. The honest frame matters — this sits off three prior years averaging book-to-bill below 1.0. Adjusted free cash flow was negative $3.7 million on the working-capital build. Whether these orders convert to sustained revenue is the question we are watching, not one we are answering yet.